MHMarek Hluchy

Marek Hluchy

*This is an algorithmically generated author record based on publicly available information.

Marek Hluchy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Eduard Kasal

    Department of Anaesthesia and Intensive Care Medicine, Charles University Medical School and Teaching Hospital, Alej svobody 80, 304 60 Plzen, Czech Republic

    1 shared publication
  • Ivan Chytra

    Department of Anaesthesiology and Intensive Care, The University Hospital and The Faculty of Medicine in Plzen - Charles University, Alej Svobody 80, 304 60, Plzen, Czech Republic

    1 shared publication
  • Jan Benes

    Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic -

    1 shared publication
  • Martin Stepan

    Department of Anesthesiology and Intensive Care Medicine, Charles University in Prague, Faculty of Medicine in Plzen, University Hospital Plzen, alej Svobody 80, 304 60, Czech Republic

    1 shared publication
  • Pavel Altmann

    Department of Anesthesiology and Intensive Care, Charles University teaching hospital, alej Svobody 80, Plzen, 304 60, Czech Republic

    1 shared publication
  • Richard Pradl

    Department of Anesthesiology and Intensive Care, Pilsen University Hospital, Faculty of Medicine, Charles University Prague, Pilsen, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    Intraoperative fluid optimization using stroke volume variation in high risk surgical patients: results of prospective randomized study

    by Jan Benes, Ivan Chytra, Pavel Altmann, Marek Hluchy, Eduard Kasal, Roman Svitak, Richard Pradl, Martin Stepan

    Introduction: Stroke volume variation (SVV) is a good and easily obtainable predictor of fluid responsiveness, which can be used to guide fluid therapy in mechanically ventilated patients. During major abdominal surgery, inappropriate fluid management may result in occult organ hypoperfusion or fluid overload in patients with compromised cardiovascular reserves and thus increase postoperative morbidity. The aim of our study was to evaluate the influence of SVV guided fluid optimization on organ functions and postoperative morbidity in high risk patients undergoing major abdominal surgery. Methods: Patients undergoing elective intraabdominal surgery were randomly assigned to a Control group (n = 60) with routine intraoperative care and a Vigileo group (n = 60), where fluid management was guided by SVV (Vigileo/FloTrac system). The aim was to maintain the SVV below 10% using colloid boluses of 3 ml/kg. The laboratory parameters of organ hypoperfusion in perioperative period, the number of infectious and organ complications on day 30 after the operation, and the hospital and ICU length of stay and mortality were evaluated. The local ethics committee approved the study. Results: The patients in the Vigileo group received more colloid (1425 ml [1000-1500] vs. 1000 ml [540-1250]; P = 0.0028) intraoperatively and a lower number of hypotensive events were observed (2[1-2] Vigileo vs. 3.5[2-6] in Control; P = 0.0001). Lactate levels at the end of surgery were lower in Vigileo (1.78 ± 0.83 mmol/l vs. 2.25 ± 1.12 mmol/l; P = 0.0252). Fewer Vigileo patients developed complications (18 (30%) vs. 35 (58.3%) patients; P = 0.0033) and the overall number of complications was also reduced (34 vs. 77 complications in Vigileo and Control respectively; P = 0.0066). A difference in hospital length of stay was found only in per protocol analysis of patients receiving optimization (9 [8-12] vs. 10 [8-19] days; P = 0.0421). No difference in mortality (1 (1.7%) vs. 2 (3.3%); P = 1.0) and ICU length of stay (3 [2-5] vs. 3 [0.5-5]; P = 0.789) was found. Conclusions: In this study, fluid optimization guided by SVV during major abdominal surgery is associated with better intraoperative hemodynamic stability, decrease in serum lactate at the end of surgery and lower incidence of postoperative organ complications. Trial registration: Current Controlled Trials ISRCTN95085011.